ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO1058

Mediators of the Kidney Protective Effects of Dapagliflozin in Patients with CKD with or Without Type 2 Diabetes

Session Information

Category: CKD (Non-Dialysis)

  • 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Schechter, Meir, Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, Netherlands
  • Jongs, Niels, Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, Netherlands
  • Chertow, Glenn, Stanford University School of Medicine, Stanford, California, United States
  • McMurray, John, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom
  • Correa-Rotter, Ricardo, The National Medical Science and Nutrition Institute Salvador Zubiran, Mexico City, Mexico
  • Rossing, Peter, Steno Diabetes Center Copenhagen, Gentofte, Denmark
  • Langkilde, Anna Maria, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
  • Toto, Robert D., Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, United States
  • Wheeler, David C., Department of Renal Medicine, University College London, London, United Kingdom
  • Heerspink, Hiddo Jan L., Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, Netherlands

The DAPA-CKD trial demonstrated that dapagliflozin attenuates progression of chronic kidney disease (CKD) in patients with and without type 2 diabetes. This post-hoc analysis assessed possible mediators of the observed kidney protective effect.


In DAPA-CKD, 4304 patients with an estimated glomerular filtration rate (eGFR) 25–75 mL/min/1.73m2 and urine albumin-to-creatinine ratio (UACR) 200–5000 mg/g were randomized to receive dapagliflozin 10 mg or placebo. The primary outcome was a composite of sustained ≥50% eGFR decline, end-stage kidney disease, or kidney or cardiovascular death. We considered biomarkers that were significantly affected by dapagliflozin versus placebo over time, as assessed using mixed effect model for repeated measures: UACR, hematocrit, HbA1c, blood pressure (systolic [SBP] and diastolic [DBP]), serum sodium and potassium, and body weight. We calculated the proportion of the effect of dapagliflozin explained by the change in each biomarker by fitting a multivariable-adjusted, time-dependent, Cox model, adjusted for baseline sex, age, body mass index, eGFR, SBP, and UACR. We estimated confidence intervals using 1000-iterations bootstrap. Analyses were repeated by type 2 diabetes status.


Compared with placebo, dapagliflozin reduced UACR (29.3% [95%CI: 25.2–33.1]), SBP (2.9mmHg [2.3–3.6]), DBP (1.0mmHg [0.6–1.4]), HbA1c (0.08% [0.03–0.14]), serum potassium (0.035mEq/L [0.012–0.057]) and body weight (0.85kg [0.61–1.08]), and increased hematocrit (2.3% [2.1–2.5]) and serum sodium (0.14mEq/L [0.02–0.26]). The effect of dapagliflozin on the primary outcome was explained by changes in hematocrit (35.5% [95%CI 24.3–69.0]), UACR (35.4% [23.0–52.8]), and SBP (4.9% [1.3–9.1]), but not through the other tested biomarkers. The proportion of dapagliflozin’s effect explained by change in hematocrit was 31.2% (20.0–70.3) in participants with type 2 diabetes, and 32.4% (14.3–76.5) in those without type 2 diabetes. The respective proportions explained by the change in UACR were 41.7% (26.1–75.9) and 16.6% (3.2–34.4).


The kidney protective effect of dapagliflozin in patients with CKD is associated with its effects on albuminuria and hematocrit.


  • Commercial Support – AstraZeneca